Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedAlliance Launches PRISTINE Study Of SELUTION SLR Drug-Eluting Peripheral Balloon

Executive Summary

SELUTION SLR is the first drug-eluting balloon accepted by the FDA as part of its breakthrough program, according to the company.

You may also be interested in...



MedAlliance Secures $50M To Aid Trials And Commercialization

Trustar Capital’s investment will allow MedAlliance to pursue commercialization of its drug eluting balloon and further its trial efforts.

US FDA Panel To Take Up Lutonix DCB Catheter For Lower-Leg Use Next Month

If approved, the device will be the first drug-coated balloon indicated specifically for use in arteries below the knee.

MedAlliance Brings SELUTION SLR Drug-Eluting Peripheral Balloon To Japan

The Swiss company is rolling out the sirolimus-eluting balloon catheter in Europe and sponsoring trials in the US. The FDA has granted it breakthrough status for three different indications.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142880

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel